Kardigan
Biotechnology company Kardigan develops novel medicines for cardiovascular disease, aiming for functional cures with drugs like Ataciguat and Danicamtiv.
Secondary Market Price
Secondary Market Price
How Kardigan Measures Up
To help you manage your Kardigan equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Kardigan's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Kardigan Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Kardigan's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Kardigan is a biotechnology research company developing medicines for cardiovascular disease. The company's current work focuses on creating functional cures rather than just managing symptoms, with late-stage programs targeting specific types of dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis. Founded in 2023, Kardigan is headquartered in South San Francisco, California, with an additional office in Princeton, New Jersey. In its first few years, the company has built a team with expertise in biotechnology and cardiovascular fields and has secured a total of $554 million through Series A and B financing rounds.
Looking forward, Kardigan plans to continue advancing its late-stage pipeline, with additional milestones anticipated in 2026. The company has made several recent announcements, including the closing of a $254 million Series B financing round in late 2025. That same year, Kardigan presented positive Phase 2 data for two of its pipeline programs: ataciguat for calcific aortic valve stenosis at the American Heart Association Scientific Sessions, and danicamtiv for genetic dilated cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting. The company also appointed Andy Pasternak as Chief Strategy Officer in 2026 to guide its long-term growth.
- Fidelity Management & Research Company
- T. Rowe Price Investment Management, Inc.
- ARCH Venture Partners
- Sequoia Heritage
- Perceptive Advisors
- Co-Founder, Tassos Gianakakos
- Co-Founder, Jay Edelberg
- Co-Founder, Bob McDowell
- Co-Founder, Leslie Leinwand
- Co-Founder, Beth McNally
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Kardigan worth joining?
Deciding whether to join Kardigan depends on your personal career goals and your assessment of the company's long-term potential. Tools like Prospect can help you model the potential future value of your equity compensation to make a more informed financial decision.
What should I do with my Kardigan stock?
The right strategy for your Kardigan stock depends on your financial goals, risk tolerance, and tax situation. Platforms like Prospect offer personalized, tax-optimized strategies for exercising options and selling shares to help you maximize your returns.
Can you sell Kardigan stock?
As a private company, Kardigan stock can typically be sold during company-approved liquidity events like tender offers or on secondary markets. Prospect provides tools to help you navigate these sales and determine which shares are the most tax-optimal to sell.
How can I find the value of my Kardigan stock?
The value of private stock like Kardigan's is typically determined by its most recent 409A valuation and prices on secondary markets. You can use platforms like Prospect to access predictive models and secondary market data to better understand your equity's potential worth.
What is Kardigan's equity worth?
The precise valuation of a private company like Kardigan is not public information and is typically set during funding rounds. To understand what your personal equity stake could be worth, you can use financial modeling tools from services like Prospect to project future value.
What is Kardigan's stock ticker symbol?
As a private, pre-IPO company, Kardigan does not have a stock ticker symbol. Ticker symbols are only assigned to companies when they become publicly traded on a stock exchange.
Can I buy or sell Kardigan stock?
Employees can typically "buy" stock by exercising their vested options, while selling is usually restricted to specific windows like tender offers or secondary sales. Financial planning platforms such as Prospect can help you create tax-efficient strategies for both exercising and selling your shares.
What is the criteria to buy or invest in Kardigan stock?
Investing in a private company like Kardigan is generally restricted to employees receiving equity compensation or accredited investors participating in formal funding rounds. The general public cannot typically buy shares until the company goes public through an IPO.
